Chlamydia W4
Description
The E.coli derived recombinant 6xHis fusion at C-terminus protein contains Chlamydia Trachomatis MOMP protein epitopes, 191-286 amino acids.
Product Specs
Product Science Overview
The identification of novel antigens for a Chlamydia trachomatis vaccine involves various techniques such as CD4+ and CD8+ T-cell expression cloning, serological expression cloning, and in silico analysis of the C. trachomatis genome . These methods help in identifying antigens that elicit human CD4+ T-cell responses, which are crucial for developing an effective vaccine .
The development of a recombinant vaccine for Chlamydia trachomatis, such as the W4 recombinant, involves prioritizing antigens that induce solid protection against the infection . Candidate vaccines are often tested in animal models, such as C57BL/6 and BALB/c mice, to evaluate their efficacy in preventing bacterial shedding and colonization of the upper genital tract . The immune response to these vaccines typically involves CD4+ T cells, which play a significant role in providing protection against the infection .
Studies have shown that interferon-gamma (IFN-γ) responses to Chlamydia trachomatis vaccine candidate proteins are associated with protection against the infection . IFN-γ responses are primarily directed against major outer membrane protein (MOMP) and polymorphic membrane proteins (Pmps) E, F, G, and H . Women with spontaneous clearance of the infection have been found to have higher magnitudes of IFN-γ responses to these proteins, suggesting that these immune responses are important for vaccine efficacy .
Chlamydia trachomatis remains a significant public health concern due to its high prevalence and the severe sequelae associated with untreated infections . The development of an effective vaccine, such as the W4 recombinant, is crucial for reducing the incidence of Chlamydia trachomatis infections and preserving reproductive health .
In conclusion, the Chlamydia trachomatis W4 recombinant vaccine represents a promising advancement in the fight against sexually transmitted infections. By targeting specific antigens and eliciting strong immune responses, this vaccine has the potential to significantly reduce the burden of Chlamydia trachomatis infections worldwide.
